Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.53 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.73 |
| ▸ | GSR | P00390 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.59 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL21925058 | 1.00 | SLC7A5 (0.73) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL3303402 | 1.00 | SLC7A5 (0.73) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL571284 | 1.00 | SLC7A5 (0.73) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL27709284 | 0.98 | SLC7A5 (0.71) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL22207546 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL2723438 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL27074660 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL22654492 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL5066575 | 0.96 | SLC7A5 (0.67) | SLC7A5GSRITGB3ITGA2BPTGS1 | |
| Tyrosine SCHEMBL27765246 | 0.95 | SLC7A5 (0.75) | SLC7A5GSRITGB3ITGA2BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063253-B | Biodegradable epoxy cross-linking agent and preparation method and application thereof | 长春圣博玛生物材料有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116063253-A | Biodegradable epoxy cross-linking agent and preparation method and application thereof | 长春圣博玛生物材料有限公司 | 2023-05-05 | — | — | CN | disclosed |
| EP-1740601-B1 | MYOSIN LIGHT CHAIN KINASE INHIBITORS AND THEIR USE | UNIV CHICAGO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20100016242-A1 | MYOSIN LIGHT CHAIN KINASE INHIBITORS AND METHODS OF USE | THE UNIVERSITY OF CHICAGO (US) | 2010-01-21 | — | — | US | disclosed |
| US-7585844-B2 | Comprising nonapeptide wherein first three amino acids and last three amino acids of sequence comprise basic amino acids, and wherein inhibitor comprises at least one D-amino acid or at least one non-hydrolyzable bond; may be used to treat intestinal diseases; infectious, ischemic, inflammatory disease | THE UNIVERSITY OF CHICAGO (US) | 2009-09-08 | — | — | US | disclosed |
| US-20050261196-A1 | Myosin light chain kinase inhibitors and methods of use | THE UNIVERSITY OF CHICAGO (US) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261196-A1 | Myosin light chain kinase inhibitors and methods of use | MYLK, MYLK2, MYLK3 | PTGS1 2263/4885PTGS2 2442/4885SLC7A5 4357/4885 |
| US-20100016242-A1 | MYOSIN LIGHT CHAIN KINASE INHIBITORS AND METHODS OF USE | MYLK, MYLK2, MYLK3 | PTGS1 2263/4885PTGS2 2442/4885SLC7A5 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.